potential cancer risk for Protopic (tacrolimus) and Elidel (pimecrolimus)
There's now concern about a potential cancer risk for Protopic (tacrolimus) and Elidel (pimecrolimus).
FDA is adding a black box warning...and will soon require you to give a Medication Guide to patients getting these drugs.
It's NOT known for sure if these drugs increase cancer risk.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote